Foundation Medicine Launches Molecular Residual Disease (MRD) Test for Research Use in Early to Late-Stage Cancers Through its FlexOMx<img src=”https://s.w.org/images/core/emoji/16.0.1/72×72/2122.png” alt=”™” class=”wp-smiley”> Lab – NEWSnet – News… as it used to be
